Fig. 2

Eaf1 and eaf2 inhibited the expression of early ventral vent family genes at blastula stage. (A) Initial expression of ved (A1-A3), vox (A6-A8) and vent (A11-A13) was increased obviously in embryos injected with eaf-ATG-MO [eaf1-MO1 (8 ng/embryo) and eaf2-MO1 (8 ng/embryo)] or with eaf-splicing-MO (A4, A5, A9, A10) [eaf1-MO3 (8 ng/embryo) and eaf2-MO3 (8 ng/embryo)] at 3.5-3.7 h, and increased expression of ved was also observed in eaf1/2 ATG morphants at 30% epiboly stage (A14-A16). (B) The significantly increased expression of the ventral genes in ATG morphants at 4 h (B1) and at 30% epiboly stage (B3) was revealed by qRT-PCR, and their slightly increased expressionin eaf2 splice morphants but not in eaf1 splice morphants was revealed by qRT-PCR (B2). (C) Expression of ventral ved (C1-C3), vox (C4-C6), and vent (C7-C9) in embryos from in-crossed eaf1 F1 heterozygous mutants, and black arrows indicated the embryos with increased expression of ved (C1), vox (C4), and vent (C7). The genotypic results for embryos with increased expression (C2, C5, C8) or normal expression (C3, C6, C9) were indicted in C10, C11, and C12 respectively. eaf1-MO1: eaf1 ATG morpholino; eaf2-MO1: eaf2 ATG morpholino; eaf1-MO3: eaf1 splicing morpholino; eaf2-MO3: eaf2 splicing morpholino. A1-A16, C1-C9, lateral view, dorsal to the right.